Jazz Pharmaceuticals PLC's stock fell by 5.04% during regular trading, crossing below the 20-day SMA. This decline comes as the broader market shows weakness, with the Nasdaq-100 down 0.71% and the S&P 500 down 0.02%.
The stock's movement is attributed to broad market weakness, despite recent positive developments regarding its Ziihera therapy. The HERIZON-GEA-01 trial results indicate significant improvements in survival rates for patients with HER2+ gastric cancer, showcasing Ziihera's potential as a new standard of care. However, the overall market sentiment has not favored the stock today.
The implications of this decline suggest that while Jazz Pharmaceuticals is making strides in oncology with Ziihera, the current market conditions are impacting investor sentiment negatively. The company plans to submit a New Drug Application (NDA) for Ziihera in 2026, which could redefine treatment standards, but today's stock performance reflects broader market challenges.
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 218.92 USD with a low forecast of 188.00 USD and a high forecast of 263.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 218.92 USD with a low forecast of 188.00 USD and a high forecast of 263.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 163.980
Low
188.00
Averages
218.92
High
263.00
Current: 163.980
Low
188.00
Averages
218.92
High
263.00
TD Cowen
Joseph Thome
Buy
maintain
$205 -> $220
2026-01-29
New
Reason
TD Cowen
Joseph Thome
Price Target
$205 -> $220
AI Analysis
2026-01-29
New
maintain
Buy
Reason
TD Cowen analyst Joseph Thome raised the firm's price target on Jazz Pharmaceuticals to $220 from $205 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.
BofA
Buy
maintain
$247 -> $263
2026-01-09
Reason
BofA
Price Target
$247 -> $263
2026-01-09
maintain
Buy
Reason
BofA raised the firm's price target on Jazz Pharmaceuticals to $263 from $247 and keeps a Buy rating on the shares following the detailed presentation of Phase 3 HERIZON-GEA-01 data at ASCO GI. Shares were under pressure after the presentation, but the firm thinks the selloff was "unwarranted" as the presentation did not yield any material findings to change the drug's approval prospects or peak sales outlook, the analyst tells investors. The firm thinks the full data look good and support a $1B peak sales forecast for Ziihera in first-line gastroesophageal adenocarcinoma, adds the analyst, who increased the view of program's odds of success to 85% from 63%.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JAZZ
Unlock Now
Morgan Stanley
Sean Laaman
Overweight
maintain
$205 -> $225
2026-01-08
Reason
Morgan Stanley
Sean Laaman
Price Target
$205 -> $225
2026-01-08
maintain
Overweight
Reason
Morgan Stanley analyst Sean Laaman raised the firm's price target on Jazz Pharmaceuticals to $225 from $205 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Piper Sandler
David Amsellem
Overweight
upgrade
$147 -> $219
2025-12-10
Reason
Piper Sandler
David Amsellem
Price Target
$147 -> $219
2025-12-10
upgrade
Overweight
Reason
Piper Sandler analyst David Amsellem raised the firm's price target on Jazz Pharmaceuticals to $219 from $147 and keeps an Overweight rating on the shares. With Jazz recently announcing positive top-line results from the pivotal HERIZON-GEA-01 study evaluating novel bispecific HER2-directed antibody zanidatamab in HER2+ first-line advanced/metastatic gastroesophageal adenocarcinoma, the firm is updating its model to reflect significantly less risk-adjustment associated with its sales estimates for the product.
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
